OptimizeRx Corp
For the period ended Dec 31, 2023. Filed Apr 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 15, 2024
OPRX$9.35-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
Item 15. Exhibits and Financial Statements Schedules
| (a) | The consolidated financial statements and exhibits listed below are filed as part of this Annual Report on Form 10-K. |
|---|
| (1) | The Company’s consolidated financial statements, the notes thereto and the report of the Independent Registered Public Accounting Firm are included in PART II, Item 8. “Financial Statements and Supplementary Data.” |
| (2) | Financial statement schedules have been omitted because they are not applicable, not required, or the required information is included in the Consolidated Financial Statements or Notes thereto. |
| (3) | Exhibits. Reference is made to Item 15(b) below. |
| (b) | Exhibits. The Exhibit Index, which immediately precedes the signature page, is incorporated by reference into this Annual Report on Form 10-K. |
|---|
| (c) | Financial Statement Schedules. Reference is made to Item 15(a)(2) above. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.